Abenava Medipharma Private Limited - Due diligence report

A 360° intelligence report on Abenava Medipharma Private Limited: trust score, financial health, credit view, compliance, directors, growth …

2012-01-16 Agra, Uttar Pradesh Active Unlisted Active Compliant
Share
AM Abenava Medipharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Abenava Medipharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
91/100
Trust Score
Low Risk

Abenava Medipharma Private Limited is assessed as Low Risk with a Trust Score of 91/100. Abenava Medipharma Private Limited is an active private limited indian non-government company incorporated in 2012, operating in the Chemicals sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 23 Jul 2026 from the latest processed filings. Abenava Medipharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
91/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (30.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Canara Bank1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NAVENDRA SINGH 01234567 Director 01/04/2018 6 yrs Approved
RENU RATHI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 75
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 14+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment93/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 30.00 Lakh already registered.
  • Compliance record supports lending.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 6 events
29 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
05 Jun 2015
Charge created
Canara Bank - 30.00 Lakh
16 Jan 2012
Incorporated
Registered with Roc Uttar Pradesh Ii
Director appointed
NAVENDRA SINGH (Director)
Director appointed
RENU RATHI (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 3 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Glowide Pharmaceuticals Private Limited U74900MH2016PTC273586 Nagpur, Maharashtra, India
Jiomed Healthcare Private Limited U74999TG2017PTC115054 Hyderabad, Telangana, India
Ran Multi Services Private Limited U74120UP2015PTC070732 Lucknow, Uttar Pradesh, India
Suvarna Additives Private Limited U24100MH2011PTC221076 Navi Mumbai, Maharashtra, India
Suryadarshan Ayurveda Private Limited U74999GJ2018PTC103551 Umbergaon, Gujarat, India
Labh-Sohn Chemicals Private Limited U74899DL1971PTC005702 New Delhi, Delhi, India
Crsons Healthcare Private Limited U51101PN2013PTC148328 Pune, Maharashtra, India
Venkateshwara Speciality Fertilizers (India)Private Limited U24111PN2017PTC171319 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Abenava Medipharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Abenava Medipharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Abenava Medipharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 91/100, distress signals and MSME payment-delay disclosures - know whether Abenava Medipharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Abenava Medipharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Abenava Medipharma Private Limited an active company?

Abenava Medipharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Abenava Medipharma Private Limited financially healthy?

Abenava Medipharma Private Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Abenava Medipharma Private Limited?

Its overall Trust Score is 91/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Abenava Medipharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Abenava Medipharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Abenava Medipharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Abenava Medipharma Private Limited?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.